´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2024 Spring Semi-Annual Meeting (2ÀÏÂ÷) : 2024-05-11
±³À°ÀÏÀÚ : 2024-05-11
±³À°Àå¼Ò : ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ : KGOG 2024 Spring Semi-Annual Meeting (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : ±èÇý¼÷
¿¬¶ôó : 02-512-5420
À̸ÞÀÏ : kelly.kim1436@gmail.com
±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : °æ±âµµ
±³À°½Ã°£ : 7 ½Ã°£ 37ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í KGOG : Korean Gynecologic Oncology Group »ç´Ü¹ýÀÎ ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ ¾àÀÚÀÔ´Ï´Ù.*ÇÁ·Î±×·¥¿¡ KGOG·Î µÇ¾îÀÖ´Â ºÎºÐ Âü°í ºÎŹµå¸³´Ï´Ù.
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 09:00~09:15 The Role and Utilization of Biobanks: a Key to the Translational Research and Drug Development ½ÅÀº¾Æ(¿ëÀμ¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 09:15~09:30 Global Biobank Landscape and Operations: Insights from NCI (NRG, SWOG), ENGOT, and GOG-F ±Çº´¼ö(°æÈñÀÇ·á¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 09:30~09:45 Application of bioinformatics to investigate cancer etiology and provide clinical implications: analyzing large-scale, multi-dimensional data including biobank sources. ÀÌ¿ì¾ß(National Institutes of Health)
Åä·Ð 05¿ù 11ÀÏ Room A 09:45~09:50 Discussion ÇÑ°üÈñ, Ȳ¿ì¿¬(»ó°è¹éº´¿ø, °æÈñ´ëº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room B 09:00~09:15 Up-to-date Management & Guideline status for Endometrial cancer patients ±è¹Î±Ô(»ï¼ºÃ¢¿øº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room B 09:15~09:30 KGOG2035/NRG-GY026 ¡°A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA¡± ÀÌÀº¼±(´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸)
±³À°½Ã°£ 05¿ù 11ÀÏ Room B 09:30~09:45 KGOG3067/SOCCER-P ¡°A Randomized Phase II Study of Secondary Cytoreductive Surgery in Patients with Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance¡± ±è¹Î¼(´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸)
Åä·Ð 05¿ù 11ÀÏ Room B 09:45~09:50 Discussion ()
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:00~10:03 1. Intorduction/Review of ongoing study (ÀÚÀ¯) ÃÖÇöÁø(Á߾Ӵ뱤¸íº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:03~10:10 KGOG 3051/NRG-GY019 : A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum (ÀÚÀ¯) ±è±âµ¿(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:10~10:17 KGOG 3053/NRG-CC008 clinical trial : A Non-Randomized Prospective Clinical Trail Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROC) (ÀÚÀ¯) ÃÖÇöÁø(Á߾Ӵ뱤¸íº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:17~10:24 KGOG 3055/JGOG 3024 : Biobank cohort study in subjects who have not developed ovarian cancer to determine BRCA1/2 gene variants and the incidence, clinicopathological characteristics, and risk factors in the development of cancer (ÀÚÀ¯) ÀÌÁ¤¿ø(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:24~10:31 KGOG 3059 : A cohort study to assess the safety and efficacy of PARP inhibitor maintenance after first-line therapy of Korean women with advanced ovarian/fallopian/peritoneal cancer (ÀÚÀ¯) ÀÌÀºÁÖ(Á߾Ӵ뺴¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:31~10:38 KGOG 3064/KROG 2204 : Prospective Multi-institutional Phase III Trial of Salvage Systemic Therapy with or without Stereotactic ABl ative Radiation Therapy for Recurrent Ovarian Cancer (ÀÚÀ¯) ±è¿ë¹è(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:38~10:45 KGOG 3067 : A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance (SOCCER-P) (ÀÚÀ¯) Á¶Çö¿õ(°í´ë±¸·Îº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 10:45~10:55 Closed study : presentation Phase II trial evaluating the Efficacy and safety of physician chosen chemotherapy with hormonaL therapy in patientS with heavily pretreated Advanced epithelial ovarian, fallopian tube or primary peritoneal cancer: A multicenter pilot study (ELSA) (ÀÚÀ¯) À̹æÇö(ÀÎÇϴ뺴¿ø)
ÈÞ½Ä 05¿ù 11ÀÏ Lobby 11:00~11:15 Coffee Break ()
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:15~11:20 Cervix, Vulva, Vagina Committee : List of ongoing KGOG trials (ÀÚÀ¯) Á¤¿ë¿í(°³²Â÷º´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:20~11:24 Featuring KGOG protocol: 1. completed protocol : SELPAX (ÀÚÀ¯) ±è¹®È«(¿øÀڷº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:24~11:28 Featuring KGOG protocol: 2. ongoing protocol : AFTER (ÀÚÀ¯) ½É½ÂÇõ(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:28~11:32 Featuring KGOG protocol: 3. new protocol : CRASH (ÀÚÀ¯) ±è±âµ¿(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:32~11:42 Overview of recent trials with different setting: 1.early cervical cancer: SHAPE, ConCerv, SENTIX (ÀÚÀ¯) À̼±¹Ì(°í´ë¾È¾Ïº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:42~11:52 Overview of recent trials with different setting: 2. locally advanced cancer: INTERLACE, KNA18, (ÀÚÀ¯) ±èÁ¤Ã¶(¼øõÇâ´ëºÎõº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 11:52~12:02 Overview of recent trials with different setting: 3. Advanced/ Metastatic cancer : BEATcc, KN826 (ÀÚÀ¯) ÀÌÁöÇö(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 12:02~12:12 Overview of recent trials with different setting: 4. 2nd line therapy : EMPOWER, InnovaTV301 (ÀÚÀ¯) ¼ÛÈñ°æ(ÀÎõ¼º¸ðº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 12:15~12:35 Sustained benefit of olaparib in BRCAm patients with newly diagnosed ovarian cancer. ¹é¹ÎÇö(°¿ø´ëÇб³º´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 12:35~12:55 How to manage adverse events and dose modification for PARP inhibitors in ovarian cancer. ¼³¾Ö¶õ(°í´ë¾È»êº´¿ø)
Åä·Ð 05¿ù 11ÀÏ Room A 12:55~13:05 Discussion ¿À¿µÅÃ(°í´ë¾È»êº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room B 12:15~12:55 New era of treatment in Endometrial cancer: Unmet needs and Look to the future ¼Û¿ëÁß(ºÎ»ê´ëº´¿ø)
Åä·Ð 05¿ù 11ÀÏ Room B 12:55~13:05 Discussion ¾î°æÁø(¿ëÀμ¼ºê¶õ½ºº´¿ø)
ÈÞ½Ä 05¿ù 11ÀÏ Lobby 13:15~13:30 Coffee Break ()
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 13:30~13:45 GOG-P/KGOG Session: Partnership Time Reporting between GOG-P & KGOG ¼ÛÀçÀ±(°í´ë¾È¾Ïº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 13:45~14:00 GOG-P/KGOG Session: Joint Papers for Intergroup Accord and SIT Á¤ÇöÈÆ(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 14:00~14:15 GOG-P/KGOG Session: Current and Upcoming Studies of GOG-P/KGOG À̼ºÁ¾(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 14:15~14:30 GOG-P/KGOG Session: Provisional KGOG-P for International SIT ±èº´±â(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 14:30~14:45 GOG-P/KGOG Session: Future Perspectives on Collaboration with GOG-P and Beyond ±è±âµ¿(ºÐ´ç¼¿ï´ëº´¿ø)
Åä·Ð 05¿ù 11ÀÏ Room A 14:45~14:55 Discussion ±è»ó¿î, ±è¹Î±Ô(¿¬¼¼¾Ïº´¿ø, »ï¼ºÃ¢¿øº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:00~15:10 Uterine Corpus-GTT Committee: KGOG Corpus Statistics Report till 2023 (ÀÚÀ¯) ±è¹Î±Ô(»ï¼ºÃ¢¿øº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:10~15:14 Review of ongoing study: 1. 2020 Fertility,1st-MPA (ÀÚÀ¯) ¹ÚÁ¤¿(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:14~15:18 Review of ongoing study: 2. 2021 TREE PRO(no LN) (ÀÚÀ¯) ±è±âµ¿(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:18~15:22 Review of ongoing study: 3. 2024 Re GTT,Keytruda (ÀÚÀ¯) ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:22~15:26 Review of ongoing study: 4. 2029 SELYE(Sentinel) (ÀÚÀ¯) ¹ÚÁ¤¿(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:26~15:30 Review of ongoing study: 5. 2031 JGOG2051:Re-MPA (ÀÚÀ¯) ¿À¿µÅÃ(°í´ë¾È»êº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:30~15:34 Review of ongoing study: 6. 2034 ECLAT:ALL LN (ÀÚÀ¯) ±èÀç¿ø(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:34~15:38 Review of ongoing study: 7. 2035 NRG GY026:1st-HER2 (ÀÚÀ¯) ±è¹Î±Ô(»ï¼ºÃ¢¿øº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:38~15:55 Uterine Corpus-GTT Committee : New Proposal ¹ÚÁ¤¿(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05¿ù 11ÀÏ Room A 15:55~16:00 Closing ()